Bank Central Asia BBCA IJ - Buy - Solid YTD Jul-24 results
BBCA’s bank-only Jul-24 earnings of IDR4.9tr (+1% m-m / +17% y-y) brings YTD Jul-24 headline profit to
TP of IDR7,600 (down from IDR8,700)
Post FY24 results, we revise our FY25-26F earnings estimates. We also add a new forecast year, FY27F. Key reasons for our revised earnings forecasts are:
1. Concern about strong loan growth of ~20% y-y, yet NII only rose by ~6% y-y in FY24. This can be attributed to the bank’s lack of loan pricing power as well as higher funding costs (reflecting tight liquidity). We think such a high level of loan growth is unlikely to be repeated in FY25F. Thus, it is no surprise that the bank is guiding for a lower loan growth of 10-12% in 2025 – a marked deceleration from 20% in 2024.
2. Slight decline in NIMs in 4Q24, reflecting our key thesis on the Indonesia banking sector. Specifically, we think that liquidity in the system will remain tight, but it should not worsen. This would reduce NIMs slightly for BMRI, which we estimate at 4.7% in 2025F, and 4.7-4.6% in 2026-27F.
Our revised earnings forecasts for FY25-26F imply earnings cuts of ~10.3-11.6%, resulting in implied ROAEs of 19.4-20.1% in FY25-27F – one of the highest in the Indonesian banking system. In our view, a near-term share price catalyst is further improvement in system liquidity. Of late, we have not only seen BI reducing the benchmark rate to 6.5% but also SRBIs blended rate to 6.715% (as of 31 Jan 2025) from 7.253% (as of 27 Dec 2024). Key catalysts include easing of SRBI issuance which relieve pressure for BMRI’s CoF
Valuation and risks
We derive our TP of IDR7,600 based on a DuPont analysis, assuming a risk-free rate of 6.5% (unchanged), an equity risk premium of 7.8% (unchanged), growth of 11.0% (unchanged), beta 1.05x (up from 1.03x) and a CAR-adjusted ROAE of 19.5% (down from 20.0%). We also use 2025F book as reference. The implied multiples at our TP are 2.3x 2025F book and 12.4x 2025F earnings (compared to current multiples of 2.5x and 13.7x, respectively). Key risks to our view are worsening macroeconomic trends, unfavorable regulatory changes, tighter liquidity competition (which would increase funding costs), worsening credit quality (which would raise credit costs), and higher opex. We also want to highlight the upcoming shareholders’ meeting with management changes a main agenda item.
Year-end 31 Dec | FY24 | FY25F | FY26F | FY27F | |||
Currency (IDR) | Actual | Old | New | Old | New | Old | New |
PPOP (bn) | 87,871 | 103,072 | 93,403 | 111,336 | 102,021 | 0 | 114,435 |
Reported net profit (bn) | 55,783 | 64,936 | 57,387 | 70,291 | 63,058 | 0 | 70,820 |
Normalised net profit (bn) | 55,783 | 64,936 | 57,387 | 70,291 | 63,058 | 0 | 70,820 |
FD normalised EPS | 597.67 | 695.74 | 614.86 | 753.11 | 675.62 | 758.78 | |
FD norm. EPS growth (%) | 1.3 | 8.6 | 2.9 | 8.2 | 9.9 | 12.3 | |
FD normalised P/E (x) | 8.6 | – | 8.4 | – | 7.6 | – | 6.8 |
Price/adj. book (x) | 1.7 | – | 1.6 | – | 1.4 | – | 1.3 |
Price/book (x) | 1.7 | – | 1.6 | – | 1.4 | – | 1.3 |
Dividend yield (%) | 6.9 | – | 7.0 | – | 7.2 | – | 7.9 |
ROE (%) | 20.5 | 21.2 | 19.4 | 20.9 | 19.6 | 20.1 | |
ROA (%) | 2.5 | 2.5 | 2.4 | 2.5 | 2.4 | 2.4 | |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Reduced from IDR 8,700 | IDR 7,600 |
Closing price 7 February 2025 | IDR 5,150 |
Implied upside | +47.6% |
Market Cap (USD mn) | 29,247.7 |
ADT (USD mn) | 44.8 |
M cap (USDmn) | 29,247.7 |
Free float (%) | 40.0 |
3-mth ADT (USDmn) | 44.8 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -8.0 | -19.8 | -25.9 |
Absolute (USD) | -8.9 | -22.5 | -28.8 |
Rel to Jakarta Stock Exchange Composite Index | -3.2 | -12.9 | -19.1 |
Erwin Wijaya (erwin.wijaya@verdhana.id)